NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗肥胖處方藥市場 (各類藥物:Bupropion & Naltrexone,Orlistat,Lorcaserin,Phentermine & Topiramate,Liraglutide,年齡群,各流通管道) - 全球產業分析,規模,佔有率,成長,趨勢,及2017∼2026年的預測

Anti-Obesity Prescription Drugs Market (By Drug Class-Bupropion & Naltrexone, Orlistat, Lorcaserin, Phentermine & Topiramate, Liraglutide; Age Group, Distribution Channel)-Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2017 - 2026

出版商 Transparency Market Research 商品編碼 587867
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
抗肥胖處方藥市場 (各類藥物:Bupropion & Naltrexone,Orlistat,Lorcaserin,Phentermine & Topiramate,Liraglutide,年齡群,各流通管道) - 全球產業分析,規模,佔有率,成長,趨勢,及2017∼2026年的預測 Anti-Obesity Prescription Drugs Market (By Drug Class-Bupropion & Naltrexone, Orlistat, Lorcaserin, Phentermine & Topiramate, Liraglutide; Age Group, Distribution Channel)-Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2017 - 2026
出版日期: 2017年11月17日內容資訊: 英文 170 Pages
簡介

全球抗肥胖處方藥市場由於全球性肥胖罹患率上升等因素,一般認為將呈現溫和增長。由於含更多膽固醇的不健康食品消費增加,促使抗肥胖處方藥需求也隨之增加。

本報告提供全球抗肥胖處方藥市場相關調查,彙整市場概要和各類藥物,年齡群,各流通管道,及各地區的趨勢,打入市場的主要企業的簡介等資料。

第1章 摘要整理

第2章 市場概要

  • 簡介
  • 市場規模與預測
  • 市場趨勢
  • 供應鏈
  • 成本結構
  • 價格分析
  • 大環境分析
  • 產品生命週期分析
  • 主要的法律規章
  • 專利
  • 經銷商清單
  • 主要參與企業的各地區市場地位

第3章 市場分析與預測

  • 各類藥物市場規模與預測
    • Bupropion & Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine & Topiramate
    • Liraglutide
  • 各年齡群市場規模與預測
    • 兒童
    • 成人
  • 各流通管道市場規模與預測
    • 院內藥局
    • 零售藥局
    • 電子商務

第4章 北美

第5章 南美

第6章 歐洲

第7章 日本

第8章 APEJ

第9章 中東·非洲

第10章 企業佔有率,競爭環境,企業簡介

  • 企業佔有率分析
  • 競爭環境
  • 企業簡介
    • VIVUS Inc.
    • Novo Nordisk A/S
    • GlaxoSmithKline PLC
    • Roche Holding AG
    • Arena Pharmaceuticals, Inc.
    • Orexigen Therapeutics, Inc.
    • Merck & Co Inc.
    • Sun Pharmaceutical Industries Limited
    • 武田藥品工業
    • Pfizer Inc.

第11章 調查方法

第12章 二次·一次來源

第13章 假設和簡稱

第14章 免責聲明

目錄

Title:
Anti-Obesity Prescription Drugs Market (By Drug Class - Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide; Age Group - Pediatric, Adult; Distribution Channel - Hospitals Pharmacies, Retail Pharmacies, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026.

Global Anti-Obesity Prescription Drugs Market: Overview

The global anti-obesity prescription drugs market is expected to witness a moderate growth attributed to growing prevalence of obesity globally. Moreover, surge in consumption of unhealthy food products that are rich in cholesterol has led to an upsurge in demand anti-obesity prescription drugs. Increasing level of chronic stress also contributes towards obesity. Moreover, consumption of psychotropic and diabetic drugs is expected to impact growth of the global anti-obesity prescription drugs market during the forecast period.

The report provides an in-depth insight on some important aspects of the global anti-obesity prescription drugs market and offers insights on the growth patterns, various factors fuelling growth of the global market, competitive landscape and important segments.

Global Anti-Obesity Prescription Drugs Market: Dynamics

Growth of the global anti-obesity prescription drugs market will mainly remain bound to various macro-economic and micro-economic factors. The report further reveals that the global anti-obesity prescription drugs market is increasingly driven by growing prevalence of obesity globally. Consumption of the food products that are rich in cholesterol continues to contribute towards obesity. Growing consumption of alcoholic beverages will also lead to increase in obesity during the forecast period.

Growing prevalence of depression has led to increasing consumption of the psychotropic drugs. Increasing side-effects of the psychotropic drug has contributed towards obesity. Growing prevalence of obesity due to increasing side-effects of psychotropic drugs has led to an upsurge in demand for obesity management. Moreover, increasing prevalence of diabetes has revved up consumption of medications such as sulfonylureas, insulin and thizolidinediones. These medications have appetite stimulating features, due to which the patients tend to eat more. Eating disorders due to antidepressants and diabetic drugs has continued to contribute towards obesity. Increasing demand for obesity management is expected to impact growth of the global anti-obesity prescription drugs market positively.

Obesity has also witnessed to be a result of increasing chronic stress globally. Increasing emotional and physical stress level leads the brain to release cortisol hormones. Release of the cortisol hormones further stimulates a person's appetite, due to which people tend to eat unhealthy food products. Increasing consumption of unhealthy food products helps people to counter their emotional and physical stress. Growing prevalence of obesity due to increasing level of stress has further led to an upsurge in demand for obesity management. Bound to these factors, the global anti-obesity prescription drugs market is expected to witness significant growth.

Global Anti-Obesity Prescription Drugs Market: Segmentation

The global anti-obesity prescription drugs market is mainly segmented into drug class, age group, distribution channel, and region. On the basis drug class, the global market is expected to be segmented as Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate and Liraglutide. Based on age group, the global market is segmented as Pediatric and Adult. By distribution channel, the global market is segmented as Hospitals Pharmacies, Retail Pharmacies and E-commerce.

Global Anti-Obesity Prescription Drugs Market: Competition

Key players in the global anti-obesity prescription drugs market are VIVUS, Inc, Orexigen Therapeutics, Inc, Novo Nordisk A/S, F Hoffmann La Roche Ltd and Arena Pharmaceuticals, Inc.

Table of Contents

1. Global Anti-Obesity Prescription Drugs Market - Executive Summary

2. Global Anti-Obesity Prescription Drugs Market Overview

  • 2.1. Introduction
    • 2.1.1. Global Anti-Obesity Prescription Drugs Market Taxonomy
    • 2.1.2. Global Anti-Obesity Prescription Drugs Market Definition
  • 2.2. Global Anti-Obesity Prescription Drugs Market Size (US$ Mn) and Forecast, 2012-2026
    • 2.2.1. Global Anti-Obesity Prescription Drugs Market Y-o-Y Growth
  • 2.3. Global Anti-Obesity Prescription Drugs Market Dynamics
  • 2.4. Supply Chain
  • 2.5. Cost Structure
  • 2.6. Pricing Analysis
  • 2.7. PESTLE Analysis
  • 2.8. Product Life Cycle Analysis
  • 2.9. Key Regulations
  • 2.10. Patents
  • 2.11. List of Distributors
  • 2.12. Key Participants Market Presence (Intensity Map) By Region

3. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast 2012-2026

  • 3.1. Global Anti-Obesity Prescription Drugs Market Size and Forecast By Drug Class, 2012-2026
    • 3.1.1. Bupropion and Naltrexone Market Size and Forecast, 2012-2026
      • 3.1.1.1. Revenue (US$ Mn) Comparison, By Region
      • 3.1.1.2. Market Share Comparison, By Region
      • 3.1.1.3. Y-o-Y growth Comparison, By Region
    • 3.1.2. Orlistat Market Size and Forecast, 2012-2026
      • 3.1.2.1. Revenue (US$ Mn) Comparison, By Region
      • 3.1.2.2. Market Share Comparison, By Region
      • 3.1.2.3. Y-o-Y growth Comparison, By Region
    • 3.1.3. Lorcaserin Market Size and Forecast, 2012-2026
      • 3.1.3.1. Revenue (US$ Mn) Comparison, By Region
      • 3.1.3.2. Market Share Comparison, By Region
      • 3.1.3.3. Y-o-Y growth Comparison, By Region
    • 3.1.4. Phentermine and Topiramate Market Size and Forecast, 2012-2026
      • 3.1.4.1. Revenue (US$ Mn) Comparison, By Region
      • 3.1.4.2. Market Share Comparison, By Region
      • 3.1.4.3. Y-o-Y growth Comparison, By Region
    • 3.1.5. Liraglutide Market Size and Forecast, 2012-2026
      • 3.1.5.1. Revenue (US$ Mn) Comparison, By Region
      • 3.1.5.2. Market Share Comparison, By Region
      • 3.1.5.3. Y-o-Y growth Comparison, By Region
  • 3.2. Global Anti-Obesity Prescription Drugs Market Size and Forecast By Age Group, 2012-2026
    • 3.2.1. Pediatric Market Size and Forecast, 2012-2026
      • 3.2.1.1. Revenue (US$ Mn) Comparison, By Region
      • 3.2.1.2. Market Share Comparison, By Region
      • 3.2.1.3. Y-o-Y growth Comparison, By Region
    • 3.2.2. Adult Market Size and Forecast, 2012-2026
      • 3.2.2.1. Revenue (US$ Mn) Comparison, By Region
      • 3.2.2.2. Market Share Comparison, By Region
      • 3.2.2.3. Y-o-Y growth Comparison, By Region
  • 3.3. Global Anti-Obesity Prescription Drugs Market Size and Forecast By Distribution Channel, 2012-2026
    • 3.3.1. Hospitals Pharmacies Market Size and Forecast, 2012-2026
      • 3.3.1.1. Revenue (US$ Mn) Comparison, By Region
      • 3.3.1.2. Market Share Comparison, By Region
      • 3.3.1.3. Y-o-Y growth Comparison, By Region
    • 3.3.2. Retail Pharmacies Market Size and Forecast, 2012-2026
      • 3.3.2.1. Revenue (US$ Mn) Comparison, By Region
      • 3.3.2.2. Market Share Comparison, By Region
      • 3.3.2.3. Y-o-Y growth Comparison, By Region
    • 3.3.3. E-commerce Market Size and Forecast, 2012-2026
      • 3.3.3.1. Revenue (US$ Mn) Comparison, By Region
      • 3.3.3.2. Market Share Comparison, By Region
      • 3.3.3.3. Y-o-Y growth Comparison, By Region

4. North America Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026

  • 4.1. Revenue (US$ Mn) Comparison, By Country
  • 4.2. Revenue (US$ Mn) Comparison, By Drug Class
  • 4.3. Revenue (US$ Mn) Comparison, By Age Group
  • 4.4. Revenue (US$ Mn) Comparison, By Distribution Channel

5. Latin America Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026

  • 5.1. Revenue (US$ Mn) Comparison, By Country
  • 5.2. Revenue (US$ Mn) Comparison, By Drug Class
  • 5.3. Revenue (US$ Mn) Comparison, By Age Group
  • 5.4. Revenue (US$ Mn) Comparison, By Distribution Channel

6. Europe Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026

  • 6.1. Revenue (US$ Mn) Comparison, By Country
  • 6.2. Revenue (US$ Mn) Comparison, By Drug Class
  • 6.3. Revenue (US$ Mn) Comparison, By Age Group
  • 6.4. Revenue (US$ Mn) Comparison, By Distribution Channel

7. Japan Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026

  • 7.1. Revenue (US$ Mn) Comparison, By Country
  • 7.2. Revenue (US$ Mn) Comparison, By Drug Class
  • 7.3. Revenue (US$ Mn) Comparison, By Age Group
  • 7.4. Revenue (US$ Mn) Comparison, By Distribution Channel

8. APEJ Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026

  • 8.1. Revenue (US$ Mn) Comparison, By Country
  • 8.2. Revenue (US$ Mn) Comparison, By Drug Class
  • 8.3. Revenue (US$ Mn) Comparison, By Age Group
  • 8.4. Revenue (US$ Mn) Comparison, By Distribution Channel

9. MEA Anti-Obesity Prescription Drugs Market Size and Forecast, 2012-2026

  • 9.1. Revenue (US$ Mn) Comparison, By Country
  • 9.2. Revenue (US$ Mn) Comparison, By Drug Class
  • 9.3. Revenue (US$ Mn) Comparison, By Age Group
  • 9.4. Revenue (US$ Mn) Comparison, By Distribution Channel

10. Global Anti-Obesity Prescription Drugs Market Company Share, Competition Landscape and Company Profiles

  • 10.1. Company Share Analysis
  • 10.2. Competition Landscape
  • 10.3. Company Profiles
    • 10.3.1. VIVUS Inc.
    • 10.3.2. Novo Nordisk A/S
    • 10.3.3. GlaxoSmithKline PLC
    • 10.3.4. Roche Holding AG
    • 10.3.5. Arena Pharmaceuticals, Inc.
    • 10.3.6. Orexigen Therapeutics, Inc.
    • 10.3.7. Merck & Co Inc.
    • 10.3.8. Sun Pharmaceutical Industries Limited
    • 10.3.9 Takeda Pharmaceutical Company Limited
    • 10.3.10 Pfizer Inc.

11. Research Methodology

12. Secondary and Primary Sources

13. Assumptions and Acronyms

14. Disclaimer

List of Tables

  • TABLE 1: Global Anti-Obesity Prescription Drugs Market Value (US$ Mn), 2012-2017
  • TABLE 2: Global Anti-Obesity Prescription Drugs Market Value (US$ Mn), 2018-2026
  • TABLE 3: Global Anti-Obesity Prescription Drugs Market Value (US$ Mn) and Y-o-Y, 2017-2026
  • TABLE 4: Global Bupropion and Naltrexone Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 5: Global Bupropion and Naltrexone Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 6: Global Bupropion and Naltrexone Segment Market Share, By Region 2012-2017
  • TABLE 7: Global Bupropion and Naltrexone Segment Market Share, By Region 2018-2026
  • TABLE 8: Global Bupropion and Naltrexone Segment Y-o-Y, By Region 2017-2026
  • TABLE 9: Global Orlistat Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 10: Global Orlistat Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 11: Global Orlistat Segment Market Share, By Region 2012-2017
  • TABLE 12: Global Orlistat Segment Market Share, By Region 2018-2026
  • TABLE 13: Global Orlistat Segment Y-o-Y, By Region 2017-2026
  • TABLE 14: Global Lorcaserin Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 15: Global Lorcaserin Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 16: Global Lorcaserin Segment Market Share, By Region 2012-2017
  • TABLE 17: Global Lorcaserin Segment Market Share, By Region 2018-2026
  • TABLE 18: Global Lorcaserin Segment Y-o-Y, By Region 2017-2026
  • TABLE 19: Global Phentermine and Topiramate Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 20: Global Phentermine and Topiramate Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 21: Global Phentermine and Topiramate Segment Market Share, By Region 2012-2017
  • TABLE 22: Global Phentermine and Topiramate Segment Market Share, By Region 2018-2026
  • TABLE 23: Global Phentermine and Topiramate Segment Y-o-Y, By Region 2017-2026
  • TABLE 24: Global Liraglutide Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 25: Global Liraglutide Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 26: Global Liraglutide Segment Market Share, By Region 2012-2017
  • TABLE 27: Global Liraglutide Segment Market Share, By Region 2018-2026
  • TABLE 28: Global Liraglutide Segment Y-o-Y, By Region 2017-2026
  • TABLE 29: Global Pediatric Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 30: Global Pediatric Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 31: Global Pediatric Segment Market Share, By Region 2012-2017
  • TABLE 32: Global Pediatric Segment Market Share, By Region 2018-2026
  • TABLE 33: Global Pediatric Segment Y-o-Y, By Region 2017-2026
  • TABLE 34: Global Adult Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 35: Global Adult Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 36: Global Adult Segment Market Share, By Region 2012-2017
  • TABLE 37: Global Adult Segment Market Share, By Region 2018-2026
  • TABLE 38: Global Adult Segment Y-o-Y, By Region 2017-2026
  • TABLE 39: Global Hospitals Pharmacies Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 40: Global Hospitals Pharmacies Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 41: Global Hospitals Pharmacies Segment Market Share, By Region 2012-2017
  • TABLE 42: Global Hospitals Pharmacies Segment Market Share, By Region 2018-2026
  • TABLE 43: Global Hospitals Pharmacies Segment Y-o-Y, By Region 2017-2026
  • TABLE 44: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 45: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 46: Global Retail Pharmacies Segment Market Share, By Region 2012-2017
  • TABLE 47: Global Retail Pharmacies Segment Market Share, By Region 2018-2026
  • TABLE 48: Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
  • TABLE 49: Global E-commerce Segment Value (US$ Mn), By Region 2012-2017
  • TABLE 50: Global E-commerce Segment Value (US$ Mn), By Region 2018-2026
  • TABLE 51: Global E-commerce Segment Market Share, By Region 2012-2017
  • TABLE 52: Global E-commerce Segment Market Share, By Region 2018-2026
  • TABLE 53: Global E-commerce Segment Y-o-Y, By Region 2017-2026
  • TABLE 54: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • TABLE 55: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • TABLE 56: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • TABLE 57: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • TABLE 58: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • TABLE 59: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • TABLE 60: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • TABLE 61: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • TABLE 62: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • TABLE 63: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • TABLE 64: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • TABLE 65: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • TABLE 66: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • TABLE 67: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • TABLE 68: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • TABLE 69: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • TABLE 70: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • TABLE 71: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • TABLE 72: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • TABLE 73: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • TABLE 74: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • TABLE 75: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • TABLE 76: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • TABLE 77: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • TABLE 78: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • TABLE 79: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • TABLE 80: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • TABLE 81: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • TABLE 82: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • TABLE 83: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • TABLE 84: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • TABLE 85: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • TABLE 86: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • TABLE 87: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • TABLE 88: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • TABLE 89: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • TABLE 90: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • TABLE 91: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • TABLE 92: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • TABLE 93: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • TABLE 94: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • TABLE 95: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • TABLE 96: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • TABLE 97: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • TABLE 98: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • TABLE 99: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • TABLE 100: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • TABLE 101: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026

List of Figures

  • FIG. 1: Global Anti-Obesity Prescription Drugs Market Value (US$ Mn), 2012-2017
  • FIG. 2: Global Anti-Obesity Prescription Drugs Market Value (US$ Mn) Forecast, 2018-2026
  • FIG. 3: Global Anti-Obesity Prescription Drugs Market Value (US$ Mn) and Y-o-Y, 2017-2026
  • FIG. 4: Global Bupropion and Naltrexone Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 5: Global Bupropion and Naltrexone Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 6: Global Bupropion and Naltrexone Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 7: Global Orlistat Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 8: Global Orlistat Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 9: Global Orlistat Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 10: Global Lorcaserin Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 11: Global Lorcaserin Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 12: Global Lorcaserin Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 13: Global Phentermine and Topiramate Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 14: Global Phentermine and Topiramate Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 15: Global Phentermine and Topiramate Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 16: Global Liraglutide Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 17: Global Liraglutide Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 18: Global Liraglutide Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 19: Global Pediatric Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 20: Global Pediatric Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 21: Global Pediatric Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 22: Global Adult Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 23: Global Adult Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 24: Global Adult Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 25: Global Hospitals Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 26: Global Hospitals Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 27: Global Hospitals Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 28: Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 29: Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 30: Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 31: Global E-commerce Segment Market Value (US$ Mn) By Region, 2012-2017
  • FIG. 32: Global E-commerce Segment Market Value (US$ Mn) By Region, 2018-2026
  • FIG. 33: Global E-commerce Segment Y-o-Y Growth Rate, By Region, 2017-2026
  • FIG. 34: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • FIG. 35: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • FIG. 36: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • FIG. 37: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • FIG. 38: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • FIG. 39: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • FIG. 40: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 41: North America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • FIG. 42: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • FIG. 43: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • FIG. 44: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • FIG. 45: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • FIG. 46: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • FIG. 47: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • FIG. 48: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 49: Latin America Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • FIG. 50: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • FIG. 51: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • FIG. 52: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • FIG. 53: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • FIG. 54: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • FIG. 55: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • FIG. 56: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 57: Europe Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • FIG. 58: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • FIG. 59: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • FIG. 60: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • FIG. 61: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • FIG. 62: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 63: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • FIG. 64: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 65: Japan Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • FIG. 66: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • FIG. 67: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • FIG. 68: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • FIG. 69: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • FIG. 70: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • FIG. 71: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • FIG. 72: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 73: APEJ Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026
  • FIG. 74: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2012-2017
  • FIG. 75: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Country 2018-2026
  • FIG. 76: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2012-2017
  • FIG. 77: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Drug Class 2018-2026
  • FIG. 78: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2012-2017
  • FIG. 79: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Age Group 2018-2026
  • FIG. 80: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2012-2017
  • FIG. 81: MEA Anti-Obesity Prescription Drugs Market Value (US$ Mn), By Distribution Channel 2018-2026